



A breakthrough in the diagnosis of Antiphospholipids Syndrome

APS

Specific Anti Cardiolipin/Vimentin kits

*An innovative method for the detection of antibodies
against a complex between
cardiolipin and vimentin*

code	Description	Sensitivity	Specificity
DKO118	Anti Cardiolipin/Vimentin IgG	0,09 AU/mL*	93,8%
DKO127	Anti Cardiolipin/Vimentin IgM	0,14 AU/mL	95,1%
DKO143	Anti Cardiolipin/Vimentin Screen	0,09 AU/mL* 0,14 AU/mL*	93,8% 95,1%



a breakthrough in the diagnosis of Antiphospholipids Syndrome

APS

Specific Anti Cardiolipin/Vimentin kits

An innovative method for the detection of antibodies against a complex between cardiolipin and an intermediate filament protein.

There are many cases defined as false negative, or seronegative, that present secondary clinical symptoms of APS (such as migraine, marked livedo reticularis, thrombocytopenia, consecutive miscarriages, heart valve problems) and are consistently negative for such antibodies detected with the traditional anti cardiolipin test.

Therefore these patients cannot be diagnosed with APS according to the consensus criteria, even if affected by the antiphospholipids syndrome.

The present innovative method puts a milestone in the diagnosis of APS, delivering results consistent with the clinical diagnosis.

The present kit is not intended to replace the traditional anti Cardiolipin test; the combined use of the APS Ultrasensitive Cardiolipin, with the below Diametra kits provides an unparalleled reliability in the diagnosis of APS.

Anti Cardiolipin-Vimentin (IgG +IgM) antibodies were significantly increased in LA positive patients (positive in 56/199, 28%) as compared to healthy donors (positive in 9/81, 11.1%).

In particular, Anti Cardiolipin-Vimentin (IgG +IgM) antibodies were positive in 28/74 (37.8%) of LA-positive and/or aCL/anti- β 2GPI-positive patients, but also in 28/125 (22.4%) LA-positive patients who tested negative for aCL/anti- β 2GPI antibodies.

Moreover, 13/56 (23.2%) of LA-negative and aCL/anti- β 2GPI-negative SLE patients presented positive Anti Cardiolipin-Vimentin (IgG +IgM) antibodies.

Finally, 42/132 (31.8%) SLE patients and 12/44 (27.3) patients with definite APS presented positive Anti Cardiolipin-Vimentin (IgG +IgM) antibodies.

THROMBOSIS LINE

DKO110	Anti β 2 Glycoprotein 1 IgG
DKO111	Anti β 2 Glycoprotein 1 IgM
DKO112	Anti Cardiolipin IgM
DKO113	Anti Cardiolipin IgG
DKO114	Anti Phospholipid Screen
DKO118	Anti Cardiolipin/Vimentin IgG
DKO127	Anti Cardiolipin/Vimentin IgM
DKO143	Anti Cardiolipin/Vimentin Screen
DKO144	Anti Cardiolipin Screen
DKO145	Anti β 2 Glycoprotein 1 Screen

Diametra Srl - Head Office

20090 Segrate - Milano - Italy
Via Garibaldi, 18
Ph +39.02.21.39.184 - Fax +39.02.21.33.354
V.A.T. - IT 12585340156

www.diametra.com
info@diametra.com